Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1454124

Predictive Diagnostic Value of Mean Platelet Volume to Platelet Count and Neutrophil to Lymphocyte Ratios in the Gray Zone of Prostate Cancer with tPSA between 4 to 10 ng/mL

Provisionally accepted
xinyu yi xinyu yi 1jin li jin li 1*yilin li yilin li 2*tao huang tao huang 1*baiyi xiong baiyi xiong 1*feng zhang feng zhang 1*zhaoyi zhao zhaoyi zhao 1*
  • 1 Xiangtan Central Hospital, Xiangtan, China
  • 2 Nanchang University, Nanchang, Jiangxi Province, China

The final, formatted version of the article will be published soon.

    Objective: Exploration of the Predictive Diagnostic Value of Mean Platelet Volume to Platelet Count Ratio (MPV/PLT,PVI) and Neutrophil-to-Lymphocyte Ratio (NLR) in the tPSA Gray Zone of Prostate Cancer Methods: A retrospective study was conducted on 65 prostate cancer (Pca) patients and 52 benign prostatic hyperplasia (BPH) patients who underwent transperineal prostate biopsy at Xiangtan Central Hospital from December 2021 to December 2023. Descriptive statistics and logistic regression models were used to investigate the predictive diagnostic value of PVI and NLR in the tPSA gray zone of prostate cancer. Receiver operating characteristic (ROC) curves were constructed based on PVI and NLR values to determine the classification thresholds. Results:A total of 117 patients were enrolled, including 65 cases of PCa and 52 cases of BPH. There were no statistically significant differences in age, BMI, history of hypertension, history of diabetes, history of coronary heart disease, pre-biopsy white blood cell count, history of drinking, history of smoking, and tPSA between the PCa and BPH patients. The results of logistic regression analysis showed that PVI (OR=2.03, 95%CI: 1.34~3.07, P<0.00) and NLR (OR=0.32, 95%CI: 0.18~0.58, P<0.00) were independent predictors for diagnosing prostate cancer in the tPSA gray zone (VIF=1.04).The maximum area under the curve (AUC) for PVI was 0.70, with an optimal cut-off value of 0.05 (P≤0.01). The maximum AUC for NLR was 0.76, with an optimal cut-off value of 2.86 (P≤0.01).The calibration curve showed good consistency between the predicted and actual outcomes in both the PCa and BPH groups, indicating that the nomogram model had good predictive performance.the area under the curve (AUC) for PVI was the largest at 0.70, with an optimal cutoff value of 0.05 (P ≤ 0.01). The AUC for NLR was the largest at 0.76, with an optimal cutoff value of 2.86 (P ≤ 0.01). Conclusion:PVI and NLR have certain predictive diagnostic value for Pca in the tPSA gray zone, and appropriate use of PVI and NLR can improve the positive rate of early screening for Pca in the gray zone.

    Keywords: PVI, NLR (Neutrophil-to-Lymphocyte Ratio), prostate cancer, tPSA Gray Zone, predictive

    Received: 24 Jun 2024; Accepted: 16 Sep 2024.

    Copyright: © 2024 yi, li, li, huang, xiong, zhang and zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    jin li, Xiangtan Central Hospital, Xiangtan, China
    yilin li, Nanchang University, Nanchang, 330031, Jiangxi Province, China
    tao huang, Xiangtan Central Hospital, Xiangtan, China
    baiyi xiong, Xiangtan Central Hospital, Xiangtan, China
    feng zhang, Xiangtan Central Hospital, Xiangtan, China
    zhaoyi zhao, Xiangtan Central Hospital, Xiangtan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.